Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
Spinal muscular atrophy (SMA), a neurodegenerative disease, is the second most common genetic disorder and the leading genetic cause of infantile death. SMA arises from the loss of Survival Motor Neuron-1 (SMN1), leading to degeneration of lower motor neurons and, consequently, the atrophy of voluntary muscles. A duplicated copy gene called SMN2 exists in humans. SMN2 is unable to fully compensate for the loss of SMN1 because it produces very low levels of functional SMN protein due to an alternative splicing event. A C/T transition in SMN2 exon 7 results in a transcript lacking exon 7 and, therefore, creates a truncated SMN protein that cannot fully compensate for the loss of SMN1. However, SMN2 is an ideal target for therapeutic strategies that redirect this critical splicing event. Previously, we developed the first trans-splicing strategy to increase the full-length mRNA and functional SMN protein from the SMN2 gene. To improve the trans-splicing efficacy, we then developed a single-vector system that expressed a trans-splicing RNA (tsRNA) and an antisense blocking the downstream splice site. This single vector greatly enhanced trans-splicing of SMN2 transcripts in vitro and in vivo. In this report, we have added a neurotrophic factor [insulin-like growth factor (IGF)-1] to this single vector to determine whether neuroprotection and SMN induction provide greater protection in an SMA animal model. Intracerebroventricular injection of the trans-splicing/IGF vector significantly increased SMN protein in brain and spinal cord of SMAΔ7 mice and lessened the severity of disease in a more severe mouse model as evidenced by an extension of life span and increased body mass.
Shababi
Monir
M
Department of Veterinary Pathobiology, Bond Life Sciences Center, University of Missouri, Columbia, MO 65211, USA. ShababiM@missouri.edu
Glascock
Jacqueline
J
Lorson
Christian L
CL
D000818:Animals; D004195:Disease Models, Animal; D005091:Exons; D020440:Gene Duplication; D015316:Genetic Therapy; D005822:Genetic Vectors; D057967:Infusions, Intraventricular; D007334:Insulin-Like Growth Factor I / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009134:Muscular Atrophy, Spinal / Q000235:genetics / Q000628:therapy*; D010957:Plasmids; D017411:Ribonucleoproteins, Small Nuclear / Q000235:genetics; D055540:Survival of Motor Neuron 2 Protein / Q000235:genetics; D020040:Trans-Splicing
D017411:Ribonucleoproteins, Small Nuclear; C526477:SMN2 protein, human; D055540:Survival of Motor Neuron 2 Protein; C519530:insulin-like growth factor-1, mouse; D007334:Insulin-Like Growth Factor I